Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.68 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | BLVRB | P30043 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | F11 | P03951 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25083600 | 0.90 | XDH (0.56) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL9275546 | 0.86 | XDH (0.53) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL469731 | 0.84 | CDC7 (0.58) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL30804867 | 0.84 | CDC7 (0.58) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL3379629 | 0.84 | KDM4E (0.65) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL1331587 | 0.84 | XDH (0.64) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL19523344 | 0.84 | XDH (0.64) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL2184198 | 0.83 | XDH (0.57) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL19523322 | 0.82 | XDH (0.63) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL19523320 | 0.82 | RAB9A (0.67) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613780-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | Takeda Pharmaceuticals U.S.A., Inc. (US) | 2013-07-17 | — | — | EP | claimed |
| US-20130143886-A1 | METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-2582812-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | Takeda Pharmaceuticals U.S.A., Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| US-20130012553-A1 | METHODS FOR STABILIZING JOINT DAMAGE IN SUBJECTS USING XANTHINE OXIDOREDUCTASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2013-01-10 | — | — | US | claimed |
| US-20120065236-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2012-03-15 | — | — | US | claimed |
| US-20120065215-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2012-03-15 | — | — | US | claimed |
| WO-2012033941-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2012-03-15 | — | — | WO | claimed |
| US-20120065207-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2012-03-15 | — | — | US | claimed |
| US-20110311620-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2011-12-22 | — | — | US | claimed |
| WO-2011159745-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. (US) | 2011-12-22 | — | — | WO | claimed |
| EP-1957064-A2 | TREATMENT OF QT INTERVAL PROLONGATION AND DISEASES ASSOCIATED THEREWITH | Tap Pharmaceutical Products, Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2008089296-A1 | METHODS FOR PREVENTING OR REDUCING THE NUMBER OF GOUT FLARES USING XANTHINE OXIDOREDUCTASE INHIBITORS AND ANTI-INFLAMMATORY AGENTS | TAKEDA PHARMACEUTICALS NORTH AMERICA (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1940397-A2 | METHODS FOR TREATING HYPERTENSION | Tap Pharmaceutical Products, Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2008064015-A1 | METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS | TAKEDA PHARMACEUTICALS NORTH AMERICA (US) | 2008-05-29 | — | — | WO | claimed |
| EP-1883405-A2 | METHODS FOR TREATING NEPHROLITHIASIS | TAP Pharmaceutical Products, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| US-20070167454-A1 | Methods for treating hypertension | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-07-19 | — | — | US | claimed |
| WO-2007062028-A2 | TREATMENT OF QT INTERVAL PROLONGATION AND DISEASES ASSOCIATED THEREWITH | TAP PHARMACEUTICAL PRODUCTS, INC. (US) | 2007-05-31 | — | — | WO | claimed |
| WO-2007019153-A2 | METHODS FOR TREATING HYPERTENSION | TAP PHARMACEUTICAL PRODUCTS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| WO-2006121995-A2 | METHODS FOR TREATING NEPHROLITHIASIS | TAP PHARMACEUTICAL PRODUCTS, INC. (US) | 2006-11-16 | — | — | WO | claimed |
| US-20060252808-A1 | Methods for treating nephrolithiasis | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2006-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065215-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | XDH, HPRT1, TPMT | XDH 1/4885TARBP2 909/4885ABCC4 954/4885 |
| US-20060252808-A1 | Methods for treating nephrolithiasis | XDH, OAT, LPO | XDH 1/4885TARBP2 4575/4885ABCC4 2152/4885 |
| US-20120065207-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | XDH, HPRT1, TPMT | XDH 1/4885TARBP2 909/4885ABCC4 954/4885 |
| US-20070167454-A1 | Methods for treating hypertension | XDH, REN, CYP11B2 | XDH 1/4885TARBP2 4825/4885ABCC4 3492/4885 |
| US-20130143886-A1 | METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS | XDH, GLS, REN | XDH 1/4885TARBP2 4837/4885ABCC4 2529/4885 |
| US-20120065236-A1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | XDH, HPRT1, TPMT | XDH 1/4885TARBP2 909/4885ABCC4 954/4885 |
| US-20110311620-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | XDH, PNPO, DUOX1 | XDH 1/4885TARBP2 3493/4885ABCC4 706/4885 |
| US-20130012553-A1 | METHODS FOR STABILIZING JOINT DAMAGE IN SUBJECTS USING XANTHINE OXIDOREDUCTASE INHIBITORS | XDH, AOX1, NQO1 | XDH 1/4885TARBP2 2686/4885ABCC4 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.